JPS6153325B2 - - Google Patents
Info
- Publication number
- JPS6153325B2 JPS6153325B2 JP53000465A JP46578A JPS6153325B2 JP S6153325 B2 JPS6153325 B2 JP S6153325B2 JP 53000465 A JP53000465 A JP 53000465A JP 46578 A JP46578 A JP 46578A JP S6153325 B2 JPS6153325 B2 JP S6153325B2
- Authority
- JP
- Japan
- Prior art keywords
- ticlopidine
- cancer
- tumor cells
- rats
- control group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 23
- 201000011510 cancer Diseases 0.000 claims description 19
- 206010027476 Metastases Diseases 0.000 claims description 11
- 230000009401 metastasis Effects 0.000 claims description 11
- 230000001093 anti-cancer Effects 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 32
- 241000700159 Rattus Species 0.000 description 24
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 23
- 229960005001 ticlopidine Drugs 0.000 description 23
- 210000004881 tumor cell Anatomy 0.000 description 16
- 230000001394 metastastic effect Effects 0.000 description 12
- 206010061289 metastatic neoplasm Diseases 0.000 description 12
- 210000004072 lung Anatomy 0.000 description 10
- 230000037396 body weight Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 6
- 238000010253 intravenous injection Methods 0.000 description 6
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 6
- 210000003462 vein Anatomy 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 4
- 238000011161 development Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 231100000460 acute oral toxicity Toxicity 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Priority Applications (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP46578A JPS5498337A (en) | 1978-01-06 | 1978-01-06 | Anticarcinogenic and/or antimetastatic agent |
| FR7835419A FR2413910A1 (fr) | 1978-01-06 | 1978-12-15 | Medicament anti-cancereux et preventif des metastases cancereuses a base de 5-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno(3,2-c)pyridine |
| ZA00787217A ZA787217B (en) | 1978-01-06 | 1978-12-21 | Anti-cancer and cancer metastasis preventing agent |
| IT47524/79A IT1117201B (it) | 1978-01-06 | 1979-01-04 | Medicamento anticanceroso e di prevenzione per metastasi cancerose |
| DE19792900203 DE2900203A1 (de) | 1978-01-06 | 1979-01-04 | Krebshemmendes und krebsmetastasen verhinderndes arzneimittel |
| GB79470A GB2012161A (en) | 1978-01-06 | 1979-01-05 | Anti-cancer and cancer metastasis preventing agent |
| BE0/192776A BE873326A (fr) | 1978-01-06 | 1979-01-05 | Medicament anti-cancereux et preventif des metastases cancereuses |
| AU43168/79A AU519516B2 (en) | 1978-01-06 | 1979-01-05 | Composition containing 5-(2-chlorobenzyl)-4,5,6,7,-tetra- hydro-thieno (3,2-c) pyridine |
| US06/436,969 US4963559A (en) | 1978-01-06 | 1982-10-27 | Method of treating cancer and cancer metastasis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP46578A JPS5498337A (en) | 1978-01-06 | 1978-01-06 | Anticarcinogenic and/or antimetastatic agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5498337A JPS5498337A (en) | 1979-08-03 |
| JPS6153325B2 true JPS6153325B2 (US06521211-20030218-C00004.png) | 1986-11-17 |
Family
ID=11474538
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP46578A Granted JPS5498337A (en) | 1978-01-06 | 1978-01-06 | Anticarcinogenic and/or antimetastatic agent |
Country Status (9)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2612777A1 (fr) * | 1987-03-26 | 1988-09-30 | Inst Nat Sante Rech Med | Composition medicamenteuse pour le traitement et la prevention de maladies dues a une cytotoxicite a mediation cellulaire, renfermant au moins un derive de la pyridine comme principe actif |
| US5562277A (en) * | 1994-09-02 | 1996-10-08 | Chick Machine Tool, Inc. | Modular vise-like workholding system |
| WO1996026675A1 (en) * | 1995-02-28 | 1996-09-06 | Boston Scientific Corporation | Deflectable catheter for ablating cardiac tissue |
| US6043368A (en) * | 1996-09-04 | 2000-03-28 | Poli Industria Chimica, S.P.A. | Method of making thieno-pyridine derivatives |
| FR2818547B1 (fr) * | 2000-12-22 | 2006-11-17 | Oreal | Nouveaux derives c-glycosides et utilisation |
| DE602005008050D1 (de) * | 2004-05-28 | 2008-08-21 | Nycomed Gmbh | Tetrahydropyridothiophene |
| JP2008501668A (ja) * | 2004-06-04 | 2008-01-24 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | 癌の治療に使用するためのテトラヒドロピリドチオフェン |
| JP2008501768A (ja) * | 2004-06-11 | 2008-01-24 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規の化合物及びテトラヒドロピリドチオフェンの使用 |
| AU2006212224A1 (en) | 2005-02-09 | 2006-08-17 | 4Sc Ag | Tetrahydropyridothiophenes for the treatment of proliferative diseases such as cancer |
| WO2006084904A1 (en) * | 2005-02-11 | 2006-08-17 | Nycomed Gmbh | Tetrahydropyridothiophenes as antripoliferative agents for the treatment of cancer |
| US20090252706A1 (en) * | 2005-02-11 | 2009-10-08 | Klaus Pekari | Tetrahydropyridothiophenes As Antripoliferative Agents For The Treatment Of Cancer |
| JP2008542242A (ja) * | 2005-05-25 | 2008-11-27 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規のテトラヒドロピリドチオフェン |
| EP1893618A2 (en) * | 2005-05-25 | 2008-03-05 | Nycomed GmbH | Tetrahydropyridothiophenes for use in the treatment of cancer |
| WO2014087240A2 (en) * | 2012-12-04 | 2014-06-12 | Dalhousie University | Compositions, methods and kits for preventing, reducing, and eliminating cancer metastasis |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2215948B1 (US06521211-20030218-C00004.png) * | 1973-02-01 | 1976-05-14 | Centre Etd Ind Pharma |
-
1978
- 1978-01-06 JP JP46578A patent/JPS5498337A/ja active Granted
- 1978-12-15 FR FR7835419A patent/FR2413910A1/fr active Granted
- 1978-12-21 ZA ZA00787217A patent/ZA787217B/xx unknown
-
1979
- 1979-01-04 DE DE19792900203 patent/DE2900203A1/de not_active Withdrawn
- 1979-01-04 IT IT47524/79A patent/IT1117201B/it active
- 1979-01-05 AU AU43168/79A patent/AU519516B2/en not_active Ceased
- 1979-01-05 BE BE0/192776A patent/BE873326A/xx unknown
- 1979-01-05 GB GB79470A patent/GB2012161A/en not_active Withdrawn
-
1982
- 1982-10-27 US US06/436,969 patent/US4963559A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| ZA787217B (en) | 1979-12-27 |
| BE873326A (fr) | 1979-07-05 |
| FR2413910B1 (US06521211-20030218-C00004.png) | 1980-10-24 |
| GB2012161A (en) | 1979-07-25 |
| IT1117201B (it) | 1986-02-17 |
| AU519516B2 (en) | 1981-12-10 |
| AU4316879A (en) | 1979-07-12 |
| DE2900203A1 (de) | 1979-07-12 |
| US4963559A (en) | 1990-10-16 |
| FR2413910A1 (fr) | 1979-08-03 |
| JPS5498337A (en) | 1979-08-03 |
| IT7947524A0 (it) | 1979-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS6153325B2 (US06521211-20030218-C00004.png) | ||
| JP2002523463A (ja) | 全身性炎症反応症候群（ｓｉｒｓ）患者の治療でのセレンの使用と、その治療のための組成物 | |
| JPH04234323A (ja) | パーキンソン病の治療剤 | |
| BR112020008128A2 (pt) | comprimidos de liberação retardada de deferiprona e métodos para utilização dos mesmos | |
| EP0711134A1 (en) | Medicinal for protection from neurological damage | |
| JP2000191539A (ja) | ジンセノサイドＲｂ１からなる脳細胞又は神経細胞保護剤 | |
| CA2286557A1 (en) | Phorbol esters as anti-neoplastic agents | |
| Hallgren et al. | Effects of nitric oxide inhibition on duodenal function in rat: involvement of neural mechanisms | |
| AU2016295357B2 (en) | Therapeutic combinations of orally administered paclitaxel and a P-gp inhibitor for the treatment of cancer | |
| US8497300B2 (en) | Arsenic therapy for APLS-type autoimmune lymph-oproliferative syndrome in mice and humans | |
| JP3889844B2 (ja) | 筋萎縮性側索硬化症治療剤 | |
| KR100310121B1 (ko) | 티아조푸린및리바비린을사용하는종양질환의치료방법 | |
| CN115105501A (zh) | 西奥罗尼用于小细胞肺癌的治疗 | |
| CN111529526B (zh) | 一种化合物在制备治疗急性胰腺炎的药物中的用途 | |
| AU2017305661B2 (en) | New use of N,N-bis-2-mercaptoethyl isophthalamide | |
| US4335128A (en) | Process for the treatment of patients suffering from drepanocytosis | |
| US4517309A (en) | Method for the treatment of calcifying pancreatitis | |
| Porter et al. | Iron chelation | |
| WO2022122010A1 (zh) | Jak抑制剂在肾脏疾病中的应用 | |
| WO2016139740A1 (ja) | 肝線維化改善剤 | |
| Selye | On the Site of Interaction Between NAH2Po4 and MGCL2 or KCL in the Prevention of» Phosphate-Steroid-Cardiopathy « | |
| Christensen et al. | Deferoxamine toxicity in hepatoma and primary rat cortical brain cultures | |
| CN112587538A (zh) | 绞股蓝皂苷及包含绞股蓝皂苷的药物组合物在卵巢储备和功能保护中的应用 | |
| CN113712974A (zh) | 阿司匹林在制备治疗子宫内膜增生药物中的应用 | |
| CN117224554A (zh) | Capilliposide A在制备治疗溃疡性结肠炎药物中的应用 |